Alkaline phosphatase level change in patients with osteosarcoma: Its role as a predictive factor of tumor necrosis and clinical outcome

Israel Medical Association Journal

Volumn 16, Issue 1, 2014, Pages 26-32

  Khoury, Johad F ^a   Ben Arush, Myriam Wey ^a   Weintraub, Michael ^b   Waldman, Elisha ^b   Futerman, Boris ^a   Vlodavsky, Eugene ^a   Postovsky, Sergey ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b HEBREW UNIVERSITY   (Israel)

Author keywords

Alkaline phosphatase; Necrosis; Osteosarcoma; Survival

Indexed keywords

ADOLESCENT; ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENTS; CHILD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; NECROSIS; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; OSTEOSARCOMA; PROGNOSIS; RETROSPECTIVE STUDIES; SEX FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84893032081     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 2009; 115: 1531-43.
2. Ottaviani G, Jafe N. Te epidemiology of osteosarcoma. Cancer Treat Res 2009; 152: 3-13.
3. Ferrari S, Palmerini E, Staals EL, et al. Te treatment of nonmetastatic high grade osteosarcoma of the extremity: review of the Italian Rizzoli experience. Impact on the future. Cancer Treat Res 2009; 152: 275-87.
4. Bruland S, Bauer H, Alvegaard T, Smeland S. Treatment of osteosarcoma. Te Scandinavian Sarcoma Group experience. Cancer Treat Res 2009; 152: 309-18.
5. Federman N, Bernthal N, Eiber FC, Tap WD. Te multidisciplinary management of osteosarcoma. Curr Treat Options Oncol 2009; 10: 82-93.
6. Pakos EE, Nearchou AD, Grimer RJ, et al. Prognostic factors and outcomes for osteosarcoma: an international collaboration. Eur J Cancer 2009; 45: 2367-75.
7. Clark JC, Dass CR, Choong PF. A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol 2008; 134: 281-97.
8. Glasser DB, Lane JM, Huvos AG, Marcove RC, Rosen G. Survival, prognosis, and therapeutic response in osteogenic sarcoma. Te Memorial Hospital experience. Cancer 1992; 69: 698-708.
9. Bramer JA, van Linge JH, Grimer RJ, Scholten RJ. Prognostic factors in localized extremity osteosarcoma: a systematic review. Eur J Surg Oncol 2009; 35: 1030-6.
10. Bacci G, Mercuri M, Longhi A, et al. Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution. Eur J Cancer 2005; 41: 2079-85.
11. Raymond AK, Chawla SP, Carrasco CH, et al. Osteosarcoma chemotherapy effect: a prognostic factor. Semin Diagn Pathol 1987; 4: 212-36.
12. Harting MT, Lally K P, Andrassy RJ, et al. Age as a prognostic factor for patients with osteosarcoma: an analysis of 438 patients. J Cancer Res Clin Oncol 2010; 136: 561-70.
13. Bieling P, Rehan N, Winkler P, et al. Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol 1996; 14: 848-58.
14. Cho WH, Song WS, Jeon DG, et al. Differential presentations, clinical courses, and survivals of osteosarcomas of the proximal humerus over other extremity locations. Ann Surg Oncol 2010; 17: 702-8.
15. Bacci G, Picci P, Ferrari S, et al. Prognostic signifcance of serum alkaline phosphates measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy. Cancer 1993; 71: 1224-30.
16. Bacci G, Longhi A, Ferrari S, et al. Prognostic signifcance of serum alkaline phosphatase in osteosarcoma of the extremity treated with neoadjuvant chemotherapy: recent experience at Rizzoli Institute. Oncol Rep 2002; 9: 171-5.
17. Gonzalez-Billalabeitia E, Hitt R, Fernandez J, et al. Pre-treatment serum lactate dehydrogenase level is an important prognostic factor in high-grade extremity osteosarcoma. Clin Transl Oncol 2009; 11: 479-83.
18. Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 1988; 6: 329-37.
19. Bacci G, Picci P, Ferrari S, et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer 1993; 72: 3227-38.
20. Goorin AM, Schwartzentruber DJ, Devidas M, et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 2003; 21: 1574-80.
21. Moore C, Eslin D, Levy A, Roberson J, Giusti V, Sutphin R. Prognostic signifcance of early lymphocyte recovery in pediatric osteosarcoma. Pediatr Blood Cancer 2010; 55: 1096-102.
22. Jain RK. Normalization of tumor vasculature: an emerging concept in anti-angiogenic therapy. Science 2005; 307: 58-62.
23. Bacci G, Forni C, Ferrari S, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensifcation of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the fnal outcome. J Pediatr Hematol Oncol 2003; 25: 845-53.